GTC--NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics. Part of NVIDIA AI Foundations, the new BioNeMo Cloud service offering -- for both AI model training and inference -- accelerates the most time-consuming and costly stages of drug discovery. It enables researchers to fine-tune generative AI applications on their own proprietary data, and to run AI model inference directly in a web browser or through new cloud application programming interfaces (APIs) that easily integrate into existing applications. "The transformative power of generative AI holds enormous promise for the life science and pharmaceutical industries," said Kimberly Powell, vice president of healthcare at NVIDIA. "NVIDIA's long collaboration with pioneers in the field has led to the development of BioNeMo Cloud Service, which is already serving as an AI drug discovery laboratory. It provides pretrained models and allows customization of models with proprietary data that serve every stage of the drug-discovery pipeline, helping researchers identify the right target, design molecules and proteins, and predict their interactions in the body to develop the best drug candidate."

Using a pretrained AI model from Nvidia, startup Evozyne has created two proteins with significant potential in healthcare and clean energy. A joint paper released today describes the process and the biological building blocks it produced. One aims to cure a congenital disease, another is designed to consume carbon dioxide to reduce global warming. Initial results show a new way to accelerate drug discovery and more. "It's been really encouraging that even in this first round the AI model has produced synthetic proteins as good as naturally occurring ones," says Andrew Ferguson, Evozyne's co-founder and a co-author of the paper.